Duan Yongping, who just copied the bottom of Zhongyu shares some time ago, shot again.
This time, it is the bottom reading vaccine giant Moderna. The bottom reading method is still to sell put options, involving a transaction amount of about 8 million.
Duan Yongping also said that he wanted to get the vaccine of Moderna, but he didn’t get the first two injections and only got it when he got the third one.
Even if the popularity of its vaccine is good, Moderna’s recent stock price performance is not very good. Since its stock price hit a new high last August, the giant’s stock price has fallen 58%.
Duan Yongping made another move, and the 500 billion vaccine giant sold put options at a cost of about 8 million
In the early morning of Beijing time on the 16th, investment master Duan Yongping posted his trading list on his social media account.
He copied the bottom of the vaccine giant by selling put options.
He wrote, “I\’m a little interested in mRNA now, but it doesn\’t belong to my ability circle. I bet happily and force myself. I hope I can roughly understand the company within a year.”
Later, he pointed out that the order could be changed before Monday. He reduced the number of put options sold from 1000 to 300.
According to Duan Yongping’s estimation of the transaction list, when he changed the number of orders to 300, the amount of the transaction fell to about US $1.26 million, about 8 million yuan.
According to public information, Moderna is a biotechnology enterprise headquartered in Cambridge, Massachusetts. In December 2020, the US Food and Drug Administration (FDA) approved the emergency use authorization (EUA) of Moderna covid-19 vaccine. Moderna covid-19 vaccine has therefore become the second covid-19 vaccine approved by the United States after Pfizer / biontech vaccine.
Duan Yongping also claimed to have been vaccinated with Moderna. He wrote, “my third needle is mRNA. I wanted to hit the first two needles, but I didn\’t hit them. I think this company is a little interesting.”
The vaccine giant has withdrawn 58% and recently suffered a 28 million share reduction by the president
As of the close on Friday, January 14, Eastern time, the stock price of vaccine giant Moderna was US $204.73, with a market value of US $83 billion, or about 527.2 billion yuan.
Compared with the share price peak in August, Moderna’s share price has retreated by 58.85%.
Since Merck, Pfizer and other pharmaceutical companies announced that they were developing covid-19 oral medicine, the performance of US vaccine stocks has not been very good. With the development and approval of covid-19 oral drug, many investors believe that people’s concern about covid-19 will be reduced and their willingness to vaccinate will be reduced, so the trend of vaccine sector is under serious pressure.
Jefferies analyst Michael Yee said that investors believe that “if there is a simple pill to treat covid-19 virus, people will not be so afraid of covid-19 virus and will not be so inclined to vaccinate.”
In addition to Moderna, the withdrawal of vaccine enterprises such as biontech, Novavax and AstraZeneca has also been obvious in recent months.
This week, vaccine giant Moderna also encountered bad news about the reduction of senior executives’ holdings.
On Friday, January 14, Eastern time, the SEC disclosed that on January 12, Stephen Hoge, President of Moderna, reduced his holdings of 20000 Moderna shares at an average price of $219.67, worth about $4.39 million, or about 28 million yuan.
analysts disagree
Even if modern’s recent stock price performance is very poor, some analysts are still as optimistic about the company as Duan Yongping.
Earlier this year, Piper Sandler analyst Edward tenthoff reiterated the “overweight” rating of Moderna (mRNA. US) and gave a target price of $348.
Tenthoff believes that Moderna’s covid-19 vaccine business revenue will continue to promote its profitability. He predicts that the company’s covid-19 vaccine will reach US $17.5 billion in 2021 and US $21 billion in 2022.
In addition, the vaccine research and development of Moderna against Epstein Barr virus (EBV) has also made new progress. Moderna recently announced that the phase 1 clinical trial of its Epstein Barr virus (EBV) candidate vaccine mrna-1189 has completed the first patient administration. This phase 1 clinical trial is expected to recruit about 270 adult volunteers aged 18-30 to evaluate the safety and tolerance of mrna-1189. At present, there is no approved EBV vaccine on the market, and there is no vaccine that can prevent infectious mononucleosis.
Tenthoff pointed out that EBV is a common viral infection, which can lead to infectious mononucleosis; After infection, EBV remains in the human body for life. It may increase the risk of multiple sclerosis by 4-10 times and is associated with some cancers and autoimmune diseases.
However, some analysts are not optimistic about the prospect of Moderna.
Oppenheimer analyst hartaj Singh pointed out, “in the second half of this year, there were many variables that Moderna could not control, such as the intensified competition from Pfizer, the patent dispute with the National Institutes of health, and the problems around Omicron.”
Singh pointed out that Moderna’s share price soared in the first half of 2021 because the company showed that it could expand the scale of vaccine production, and it attracted more attention due to its inclusion in the S & P 500 index. Moderna’s third quarter earnings weakened investors’ positive sentiment.
According to the third quarter financial report of moderna2021 fiscal year, during the reporting period, the company realized a revenue of US $4.97 billion, much higher than US $158 million in the same period last year, but lower than the market expected US $6.21 billion. Its mRNA vaccine achieved a revenue of US $4.81 billion during the reporting period, which was also lower than the market expectation of US $6.27 billion.
In addition, Moderna also expects to provide 700 million to 800 million doses of covid-19 vaccine in 2021, lower than the previously expected 800 million to 1 billion doses; Covid-19 vaccine sales in 2021 are expected to be $15 billion to $18 billion, lower than the previously expected $20 billion.
Zerohedge commented that the impact of Moderna’s third quarterly report on stock prices was “worse”. After the release of the third quarter financial report, Moderna’s share price once fell by more than 18%.
Duan Yongping recently also copied the bottom of Zhongyu shares and sold the put options of pinduoduo and New Oriental
In addition to bottom reading, recently, Duan Yongping also made the operation of stock concept in bottom reading.
On December 8, Duan Yongping wrote through the social platform account “Avenue invisible I have type”, saying that he “bought” New Oriental (EDU. US) by selling short options expiring on December 31, and expressed his support for Yu Minhong.
On December 6, Duan Yongping copied the bottom of pinduoduo by selling put options. He said: “I can\’t understand pinduoduo’s business model, but I think their support for Shenzhen Agricultural Products Group Co.Ltd(000061) is very meaningful. I\’m ready to venture again!”.
After the news of Duan Yongping’s bottom reading came out, pinduoduo soared by 12% in one day and New Oriental soared by 6% in one day.
(time sharing market chart of New Oriental on Wednesday, December 8)
(time sharing market chart of pinduoduo on December 7)
